NDC-11 (Package) | NDC-9 (Product) | Generic Name (Ascending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55390-0453-01 | 55390-0453 | Mitomycin | Mitomycin | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct. 11, 2001 | Oct. 31, 2012 | No Longer Used | |
69605-0103-03 | 69605-0103 | Mitomycin | JELMYTO | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Instillation | May 1, 2020 | In Use | ||
72493-0103-03 | 72493-0103 | Mitomycin | JELMYTO | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Instillation | May 1, 2020 | In Use | ||
00015-3080-60 | 00015-3080 | Mitotane | Lysodren | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Adrenal Suppressant | Oral | June 1, 2009 | March 31, 2021 | No Longer Used |
55390-0083-01 | 55390-0083 | Mitoxantrone | Mitoxantrone | Chemotherapy | Antitumor Antibiotic | Anthracenedione | April 11, 2006 | May 31, 2010 | No Longer Used | ||
55390-0084-01 | 55390-0084 | Mitoxantrone | Mitoxantrone | Chemotherapy | Antitumor Antibiotic | Anthracenedione | April 11, 2006 | May 31, 2010 | No Longer Used | ||
55390-0085-01 | 55390-0085 | Mitoxantrone | Mitoxantrone | Chemotherapy | Antitumor Antibiotic | Anthracenedione | April 11, 2006 | May 31, 2010 | No Longer Used | ||
00703-4680-01 | 00703-4680 | Mitoxantrone | Mitoxantrone | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracenedione | Intravenous | April 11, 2006 | In Use | |
00703-4685-01 | 00703-4685 | Mitoxantrone | Mitoxantrone | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracenedione | Intravenous | April 11, 2006 | In Use | |
00703-4686-01 | 00703-4686 | Mitoxantrone | Mitoxantrone | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracenedione | Intravenous | April 11, 2006 | In Use | |
61703-0343-18 | 61703-0343 | Mitoxantrone | Mitoxantrone | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracenedione | Intravenous | April 11, 2006 | In Use | |
61703-0343-65 | 61703-0343 | Mitoxantrone | Mitoxantrone | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracenedione | Intravenous | April 11, 2006 | In Use | |
61703-0343-66 | 61703-0343 | Mitoxantrone | Mitoxantrone | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracenedione | Intravenous | April 11, 2006 | In Use | |
00069-0080-01 | 00069-0080 | Mitoxantrone Hydrochloride | Mitoxantrone Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracenedione | Intravenous | Dec. 12, 2012 | Dec. 31, 2016 | No Longer Used |
63020-0040-12 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sept. 15, 2021 | In Use | |
63020-0040-90 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sept. 15, 2021 | In Use | |
50242-0159-01 | 50242-0159 | Mosunetuzumab | Lunsumio | 1.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Dec. 22, 2022 | In Use | |
50242-0142-01 | 50242-0142 | Mosunetuzumab | Lunsumio | 30.0 mg/30mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Dec. 22, 2022 | In Use | |
00187-1221-03 | 00187-1221 | Nabilone | Cesamet | 1.0 mg/1 | Ancillary Therapy | Antiemetic | Cannabinoid | Oral | Nov. 1, 2009 | Nov. 13, 2017 | No Longer Used |
00187-1231-50 | 00187-1231 | Nabilone | Cesamet | 1.0 mg/1 | Ancillary Therapy | Antiemetic | Cannabinoid | Oral | March 9, 2020 | In Use | |
00037-1221-50 | 00037-1221 | Nabilone | Cesamet | 1.0 mg/1 | Ancillary Therapy | Antiemetic | Cannabinoid | Oral | March 1, 2010 | March 31, 2020 | No Longer Used |
59630-0222-07 | 59630-0222 | Naldemedine | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | July 5, 2018 | Dec. 31, 2020 | No Longer Used | |
59630-0222-30 | 59630-0222 | Naldemedine | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | July 5, 2018 | Dec. 31, 2020 | No Longer Used | |
59630-0222-90 | 59630-0222 | Naldemedine | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | July 5, 2018 | Dec. 31, 2020 | No Longer Used | |
59385-0041-07 | 59385-0041 | Naldemedine, naldemedine tosylate | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | July 1, 2020 | In Use | ||
59385-0041-30 | 59385-0041 | Naldemedine, naldemedine tosylate | SYMPROIC | 0.2 mg/1 | Ancillary Therapy | Opioid Antagonist | Oral | June 14, 2019 | In Use | ||
73042-0201-01 | 73042-0201 | Naxitamab | DANYELZA | 40.0 mg/10mL | Immunotherapy | Monoclonal Antibody | GD2 | Intravenous | Nov. 25, 2020 | In Use | |
00002-7716-01 | 00002-7716 | Necitumumab | Portrazza | 16.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Nov. 24, 2015 | In Use | |
00007-4401-01 | 00007-4401 | Nelarabine | Arranon | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 19, 2006 | Dec. 31, 2018 | No Longer Used |
00007-4401-06 | 00007-4401 | Nelarabine | Arranon | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 19, 2006 | Dec. 31, 2018 | No Longer Used |
70771-1685-01 | 70771-1685 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Nov. 17, 2021 | In Use | |
70771-1685-08 | 70771-1685 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Nov. 17, 2021 | In Use | |
70710-1839-01 | 70710-1839 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | June 24, 2022 | In Use | |
70710-1839-08 | 70710-1839 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | June 24, 2022 | In Use | |
00078-0683-06 | 00078-0683 | Nelarabine | Arranon | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Oct. 5, 2016 | In Use | |
00078-0683-61 | 00078-0683 | Nelarabine | Arranon | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug. 2, 2019 | In Use | |
43598-0142-06 | 43598-0142 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan. 9, 2023 | In Use | |
70710-1726-01 | 70710-1726 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Nov. 17, 2021 | In Use | |
70710-1726-08 | 70710-1726 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Nov. 17, 2021 | In Use | |
70437-0240-18 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
70437-0240-26 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
70437-0240-33 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | July 17, 2017 | In Use | |
69639-0101-01 | 69639-0101 | Netupitant and Palonosetron | Akynzeo | 300.0 mg/1, 0.5 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Oral | Oct. 13, 2014 | In Use | |
69639-0101-04 | 69639-0101 | Netupitant and Palonosetron | Akynzeo | 300.0 mg/1, 0.5 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Oral | Oct. 13, 2014 | In Use | |
62856-0796-01 | 62856-0796 | Netupitant and Palonosetron | Akynzeo | 300.0 mg/1, 0.5 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Oral | Oct. 13, 2014 | May 31, 2018 | No Longer Used |
62856-0796-04 | 62856-0796 | Netupitant and Palonosetron | Akynzeo | 300.0 mg/1, 0.5 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Oral | Oct. 13, 2014 | Oct. 13, 2014 | No Longer Used |
00078-0526-51 | 00078-0526 | Nilotinib | Tasigna | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct. 29, 2007 | In Use | |
00078-0526-87 | 00078-0526 | Nilotinib | Tasigna | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct. 29, 2007 | In Use | |
00078-0592-51 | 00078-0592 | Nilotinib | Tasigna | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct. 29, 2007 | In Use | |
00078-0592-87 | 00078-0592 | Nilotinib | Tasigna | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct. 29, 2007 | In Use |
Found 9,752 results in 20 milliseconds — Export these results